tiprankstipranks
Advertisement
Advertisement

ESALF Stock Latest News

Eisai’s E6742 Lupus Trial Advances: What ESALF Investors Need to Know
Company AnnouncementsEisai’s E6742 Lupus Trial Advances: What ESALF Investors Need to Know
2d ago
ESALF
Eisai’s Lenvatinib Combo Trial in Liver Cancer Reaches Completion: What Investors Should Watch Next
PremiumCompany Announcements
Eisai’s Lenvatinib Combo Trial in Liver Cancer Reaches Completion: What Investors Should Watch Next
7d ago
ESALF
Eisai Advances Early-Stage E2086 Study, Supporting Long-Term Pipeline Value
PremiumCompany Announcements
Eisai Advances Early-Stage E2086 Study, Supporting Long-Term Pipeline Value
2M ago
ESALF
Eisai’s E7090 Trial Update: A Targeted Cancer Bet With Growing Investor Relevance
PremiumCompany Announcements
Eisai’s E7090 Trial Update: A Targeted Cancer Bet With Growing Investor Relevance
2M ago
ESALF
ESALF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
ESALF Earnings this Week: How Will it Perform?
3M ago
Eisai’s MORAb-202 Trial: A Promising Step in Cancer Treatment
PremiumCompany AnnouncementsEisai’s MORAb-202 Trial: A Promising Step in Cancer Treatment
6M ago
ESALF
Eisai Co.’s Promising Study on E7386: A Game Changer in Cancer Treatment?
Premium
Company Announcements
Eisai Co.’s Promising Study on E7386: A Game Changer in Cancer Treatment?
6M ago
ESALF
Eisai’s Pediatric Epilepsy Study: A Potential Game-Changer for Investors
Premium
Company Announcements
Eisai’s Pediatric Epilepsy Study: A Potential Game-Changer for Investors
6M ago
ESALF
Eisai Co.’s E1018 Study: A Potential Game-Changer in Malaria Treatment
PremiumCompany Announcements
Eisai Co.’s E1018 Study: A Potential Game-Changer in Malaria Treatment
6M ago
ESALF
Eisai’s Tasfygo Study: A Closer Look at Safety in Biliary Tract Cancer
PremiumCompany Announcements
Eisai’s Tasfygo Study: A Closer Look at Safety in Biliary Tract Cancer
6M ago
ESALF
Eisai Co. Evaluates Fycompa’s Safety in New Clinical Study
PremiumCompany Announcements
Eisai Co. Evaluates Fycompa’s Safety in New Clinical Study
6M ago
ESALF
Eisai Co.’s Tasurgratinib Study: Key Insights for Investors
PremiumCompany Announcements
Eisai Co.’s Tasurgratinib Study: Key Insights for Investors
6M ago
ESALF
Eisai’s Lecanemab Study: A Closer Look at Alzheimer’s Treatment Safety
PremiumCompany AnnouncementsEisai’s Lecanemab Study: A Closer Look at Alzheimer’s Treatment Safety
6M ago
ESALF
Eisai’s Tazemetostat Study: A Key Update for Investors
Premium
Company Announcements
Eisai’s Tazemetostat Study: A Key Update for Investors
6M ago
ESALF
Is ESALF a Buy, Before Earnings?
Premium
Pre-Earnings
Is ESALF a Buy, Before Earnings?
9M ago
Eisai Co.’s Phase 1 Study of E7389-LF: Potential Game-Changer in Cancer Treatment?
PremiumCompany Announcements
Eisai Co.’s Phase 1 Study of E7389-LF: Potential Game-Changer in Cancer Treatment?
10M ago
ESALF
Eisai Co. Advances Cancer Treatment with E7389 Liposomal Study
PremiumCompany Announcements
Eisai Co. Advances Cancer Treatment with E7389 Liposomal Study
10M ago
ESALF
Eisai’s Lemborexant Study: A New Hope for Insomnia Treatment?
PremiumCompany Announcements
Eisai’s Lemborexant Study: A New Hope for Insomnia Treatment?
10M ago
ESALF
Eisai’s Fycompa Safety Study: A Potential Game-Changer in Epilepsy Treatment
PremiumCompany Announcements
Eisai’s Fycompa Safety Study: A Potential Game-Changer in Epilepsy Treatment
10M ago
ESALF
Eisai Co’s Strategic Initiatives and Growth Justify Buy Rating Despite Leqembi Guidance Concerns
PremiumRatingsEisai Co’s Strategic Initiatives and Growth Justify Buy Rating Despite Leqembi Guidance Concerns
12M ago
Eisai Co. Surpasses FY 2024 Expectations Amid Challenges
Premium
Company Announcements
Eisai Co. Surpasses FY 2024 Expectations Amid Challenges
12M ago
Eisai Co. Reports Cautious Optimism Amid Q3 Growth
Premium
Company Announcements
Eisai Co. Reports Cautious Optimism Amid Q3 Growth
1y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >